Bioclinica has launched a new Post-Approval Research division as part of its Global Clinical Research business segment. Leveraging its technology expertise, the service aims to streamline overall study resource requirements, and is flexible, scalable and customizable. It offers full access to real-time study metrics and transparency for all stakeholders.
 
The Post-Approval Research operates a Program Coordinating Center (PCC) with dedicated research staff and provides global operational infrastructure from centralized locations to support local languages and time differences. Also, the Patient Outreach Center (POC) offers processes and technology designed to increase patient compliance and data collection by 25-30%, compared to traditional methodologies and Patient-Reported Outcomes, according to the company.
 
“At Bioclinica, we understand the fundamental differences between the design and conduct of post-approval studies and those performed prior to approval. We believe the substantial and deep domain knowledge of our management team, coupled with our state-of the-art-technology, allows us to achieve our strategic goals in post-approval research,” said Dr. John Hubbard, president and chief executive officer, Bioclinica